- •
Multiparametric MR imaging (mpMRI) can help in evaluation of posttreatment changes after diagnosis and treatment of prostate cancer as well as for diagnosis of locally recurrent disease.
- •
After radical prostatectomy, radiation therapy, or focal therapy, there are certain expected changes in the remaining tissue.
- •
Many of the mpMRI patterns of recurrent disease are similar to those of primary prostate cancer. In diagnosis of recurrence, however, normal posttreatment changes and possible inflammation
Prostate MR Imaging for Posttreatment Evaluation and Recurrence
Section snippets
Key points
Multiparametric MR imaging after radical prostatectomy
RP is a common active treatment chosen for PCa patients with localized disease, with approximately 40% of patients undergoing definitive therapy choosing this option.18 RP includes total removal of the prostate and seminal vesicles, along with pelvic lymph node dissection to varying extents for evaluation of local metastasis.19 Subsequent pathology analysis evaluates surgical margins and lymph nodes for staging. Risk for future BCR is a consideration at this point, because certain
Multiparametric MR imaging after radiation therapy
The second most common definitive treatment chosen for stages I to III PCa is RT, given to up to 40% of patients over 65 years old and up to 25% of patients under 65 years old.42 RT can be offered as EBRT or brachytherapy. EBRT is generally used for earlier-stage disease and may be offered in forms, such as intensity-modulated RT or stereotactic body RT. In this approach, all radiation is delivered externally and focused through beams to the prostate. In contrast, brachytherapy uses radioactive
Multiparametric MR imaging after focal therapy
Focal therapy is a newly emerging treatment option for patients with localized PCa that falls within a certain criteria that allows the index tumor to be directly targeted. Focal therapy relies on use of various energies for local destruction of cancer cells in the gland, such as microwave, focal laser ablation (FLA), cryotherapy, and HIFU. Regardless of which energy is used, there are numerous posttreatment changes seen on follow-up MR imaging that are important to consider for success of
Summary
Prostate mpMRI offers promising potential for visualization of posttreatment changes and for evaluation of local recurrent disease in the context of BCR. Because the mpMRI evaluation is so important in detection of localized recurrence, it is vital that radiologists be communicative with the multidisciplinary team. The referring urologist, radiation oncologist, or medical oncologist should be aware that the radiologist will be acquiring and interpreting a dedicated MR imaging for posttreatment
References (86)
- et al.
Population-based study of long-term survival in patients with clinically localised prostate cancer
Lancet
(1997) - et al.
Focal therapy of prostate cancer: energies and procedures
Urol Oncol
(2013) - et al.
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference
Int J Radiat Oncol Biol Phys
(2006) - et al.
EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer
Eur Urol
(2014) - et al.
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
Lancet Oncol
(2010) - et al.
Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer
Radiother Oncol
(1997) - et al.
PI-RADS prostate imaging - reporting and data system: 2015, version 2
Eur Urol
(2016) - et al.
Defining prostate cancer risk after radical prostatectomy
Eur J Surg Oncol
(2014) - et al.
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
JAMA
(2005) - et al.
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience
Urol Clin North Am
(2001)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results
J Urol
Cancer control with radical prostatectomy alone in 1,000 consecutive patients
J Urol
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years
J Urol
Evaluation of suspected soft tissue lesion in the prostate bed after radical prostatectomy using 3T multiparametric magnetic resonance imaging
Magn Reson Imaging
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP)
Eur J Radiol
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer
Crit Rev Oncol Hematol
What is the best way to radiate the prostate in 2016?
Urol Oncol
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era
Int J Radiat Oncol Biol Phys
Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy
Int J Radiat Oncol Biol Phys
Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: subset analysis of a phase 1/2 trial
Pract Radiat Oncol
PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up
Int J Radiat Oncol Biol Phys
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer
Int J Radiat Oncol Biol Phys
The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy
Eur Urol
Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer
J Urol
Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study
Int J Radiat Oncol Biol Phys
Patterns of local failure following radiation therapy for prostate cancer
J Urol
Diffusion-weighted imaging of local recurrent prostate cancer after radiation therapy: comparison with 22-core three-dimensional prostate mapping biopsy
Magn Reson Imaging
Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings
Urology
MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence
Radiother Oncol
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy
Int J Radiat Oncol Biol Phys
Prostate magnetic resonance imaging for brachytherapists: anatomy and technique
Brachytherapy
Image guided photothermal focal therapy for localized prostate cancer: phase I trial
J Urol
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study
Lancet Oncol
Definition of biochemical success following primary whole gland prostate cryoablation
J Urol
Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate
Urology
Phase II evaluation of magnetic resonance imaging guided focal laser ablation of prostate cancer
J Urol
Cancer statistics, 2016
CA Cancer J Clin
Advances in prostate cancer treatment
Nat Rev Drug Discov
Analysis of clinicopathologic factors predicting outcome after radical prostatectomy
Cancer
Multiparametric magnetic resonance imaging of recurrent prostate cancer
Top Magn Reson Imaging
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition
J Clin Oncol
How to diagnose and treat focal therapy failure and recurrence?
Curr Opin Urol
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
CA Cancer J Clin
Cited by (42)
Prostate MRI and image quality: The urologist's perspective
2024, European Journal of RadiologyEvaluation of Prostate Cancer Recurrence with MR Imaging and Prostate Imaging for Recurrence Reporting Scoring System
2024, Radiologic Clinics of North AmericaMRI of the recurrent prostate cancers
2023, Magnetic Resonance Imaging of The Pelvis: A Practical ApproachMedium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease
2022, Urologic Oncology: Seminars and Original Investigations
Disclosure Statement: Authors have nothing to disclose.